{"id":12232,"date":"2024-12-03T11:59:24","date_gmt":"2024-12-03T16:59:24","guid":{"rendered":"https:\/\/ccna-ccnv.ca\/ccna_publication\/recommendations-on-imaging-in-the-context-of-alzheimers-disease-modifying-therapies-from-the-ccna-imaging-workgroup\/"},"modified":"2025-03-05T13:35:31","modified_gmt":"2025-03-05T18:35:31","slug":"recommendations-on-imaging-in-the-context-of-alzheimers-disease-modifying-therapies-from-the-ccna-imaging-workgroup","status":"publish","type":"ccna_publication","link":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/recommendations-on-imaging-in-the-context-of-alzheimers-disease-modifying-therapies-from-the-ccna-imaging-workgroup\/","title":{"rendered":"Recommendations on imaging in the context of Alzheimer&rsquo;s disease modifying therapies from the CCNA imaging workgroup"},"content":{"rendered":"<h2>Abstract<\/h2>\n<p><strong>Background<\/strong>: Disease-modifying therapies (DMTs) for Alzheimer&rsquo;s disease (AD) are emerging following successful clinical trials of therapies targeting amyloid beta (A\u03b2) protofibrils or plaques. Determining patient eligibility and monitoring treatment efficacy and adverse events, such as A\u03b2-related imaging abnormalities, necessitates imaging with MRI and PET. The Canadian Consortium on Neurodegeneration in Aging Imaging Workgroup aimed to synthesize evidence and provide recommendations on implementing imaging protocols for AD DMTs in Canada.<\/p>\n<p><strong>Methods<\/strong>: The Workgroup employed a Delphi process to develop these recommendations. Experts from radiology, neurology, biomedical engineering, nuclear medicine, MRI, and medical physics were recruited. Surveys and meetings were conducted to achieve consensus on key issues, including protocol standardization, scanner strength, monitoring protocols based on risk profiles, and optimal protocol lengths. Draft recommendations were refined through multiple iterations and expert discussions.<\/p>\n<p><strong>Results<\/strong>: The recommendations emphasize standardized acquisition imaging protocols across manufacturers and scanner strengths to ensure consistency and reliability of clinical treatment decisions; tailored monitoring protocols based on DMTs\u2019 safety and efficacy profiles; consistent monitoring regardless of perceived treatment efficacy; and MRI screening on 1.5T or 3T scanners with adapted protocols. An optimal protocol length of 20 to 30 minutes was deemed feasible; specific sequences are suggested.<\/p>\n<p><strong>Conclusion:<\/strong> The guidelines aim to enhance imaging data quality and consistency, facilitating better clinical decision-making and improving patient outcomes. Further research is needed to refine these protocols and address evolving challenges with new DMTs. It is recognized that administrative, financial, and logistical capacity to deliver additional MRI and PET scans require careful planning.<\/p>\n","protected":false},"author":19,"featured_media":0,"template":"","meta":{"_acf_changed":false},"studies-relation":[153],"class_list":["post-12232","ccna_publication","type-ccna_publication","status-publish","hentry","studies-relation-neuroimaging-fr"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Recommendations on imaging in the context of Alzheimer&#039;s disease modifying therapies from the CCNA imaging workgroup - CCNA - CCNV<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/recommendations-on-imaging-in-the-context-of-alzheimers-disease-modifying-therapies-from-the-ccna-imaging-workgroup\/\" \/>\n<meta property=\"og:locale\" content=\"fr_CA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Recommendations on imaging in the context of Alzheimer&#039;s disease modifying therapies from the CCNA imaging workgroup - CCNA - CCNV\" \/>\n<meta property=\"og:description\" content=\"Abstract Background: Disease-modifying therapies (DMTs) for Alzheimer&rsquo;s disease (AD) are ...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/recommendations-on-imaging-in-the-context-of-alzheimers-disease-modifying-therapies-from-the-ccna-imaging-workgroup\/\" \/>\n<meta property=\"og:site_name\" content=\"CCNA - CCNV\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-05T18:35:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/CCNA.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimation du temps de lecture\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/recommendations-on-imaging-in-the-context-of-alzheimers-disease-modifying-therapies-from-the-ccna-imaging-workgroup\/\",\"url\":\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/recommendations-on-imaging-in-the-context-of-alzheimers-disease-modifying-therapies-from-the-ccna-imaging-workgroup\/\",\"name\":\"Recommendations on imaging in the context of Alzheimer's disease modifying therapies from the CCNA imaging workgroup - CCNA - CCNV\",\"isPartOf\":{\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#website\"},\"datePublished\":\"2024-12-03T16:59:24+00:00\",\"dateModified\":\"2025-03-05T18:35:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/recommendations-on-imaging-in-the-context-of-alzheimers-disease-modifying-therapies-from-the-ccna-imaging-workgroup\/#breadcrumb\"},\"inLanguage\":\"fr-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/recommendations-on-imaging-in-the-context-of-alzheimers-disease-modifying-therapies-from-the-ccna-imaging-workgroup\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/recommendations-on-imaging-in-the-context-of-alzheimers-disease-modifying-therapies-from-the-ccna-imaging-workgroup\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ccna-ccnv.ca\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Recommendations on imaging in the context of Alzheimer&#8217;s disease modifying therapies from the CCNA imaging workgroup\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#website\",\"url\":\"https:\/\/ccna-ccnv.ca\/fr\/\",\"name\":\"Canadian Consortium on Neurodegeneration in Aging\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#organization\"},\"alternateName\":\"CCNA - CCNV\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ccna-ccnv.ca\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#organization\",\"name\":\"Canadian Consortium on Neurodegeneration in Aging\",\"alternateName\":\"CCNA - CCNV\",\"url\":\"https:\/\/ccna-ccnv.ca\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-CA\",\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/ccna-logo-on-white-background.jpg\",\"contentUrl\":\"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/ccna-logo-on-white-background.jpg\",\"width\":696,\"height\":696,\"caption\":\"Canadian Consortium on Neurodegeneration in Aging\"},\"image\":{\"@id\":\"https:\/\/ccna-ccnv.ca\/fr\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Recommendations on imaging in the context of Alzheimer's disease modifying therapies from the CCNA imaging workgroup - CCNA - CCNV","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/recommendations-on-imaging-in-the-context-of-alzheimers-disease-modifying-therapies-from-the-ccna-imaging-workgroup\/","og_locale":"fr_CA","og_type":"article","og_title":"Recommendations on imaging in the context of Alzheimer's disease modifying therapies from the CCNA imaging workgroup - CCNA - CCNV","og_description":"Abstract Background: Disease-modifying therapies (DMTs) for Alzheimer&rsquo;s disease (AD) are ...","og_url":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/recommendations-on-imaging-in-the-context-of-alzheimers-disease-modifying-therapies-from-the-ccna-imaging-workgroup\/","og_site_name":"CCNA - CCNV","article_modified_time":"2025-03-05T18:35:31+00:00","og_image":[{"width":1200,"height":675,"url":"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/CCNA.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Estimation du temps de lecture":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/recommendations-on-imaging-in-the-context-of-alzheimers-disease-modifying-therapies-from-the-ccna-imaging-workgroup\/","url":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/recommendations-on-imaging-in-the-context-of-alzheimers-disease-modifying-therapies-from-the-ccna-imaging-workgroup\/","name":"Recommendations on imaging in the context of Alzheimer's disease modifying therapies from the CCNA imaging workgroup - CCNA - CCNV","isPartOf":{"@id":"https:\/\/ccna-ccnv.ca\/fr\/#website"},"datePublished":"2024-12-03T16:59:24+00:00","dateModified":"2025-03-05T18:35:31+00:00","breadcrumb":{"@id":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/recommendations-on-imaging-in-the-context-of-alzheimers-disease-modifying-therapies-from-the-ccna-imaging-workgroup\/#breadcrumb"},"inLanguage":"fr-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/recommendations-on-imaging-in-the-context-of-alzheimers-disease-modifying-therapies-from-the-ccna-imaging-workgroup\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ccna-ccnv.ca\/fr\/ccna_publication\/recommendations-on-imaging-in-the-context-of-alzheimers-disease-modifying-therapies-from-the-ccna-imaging-workgroup\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ccna-ccnv.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Recommendations on imaging in the context of Alzheimer&#8217;s disease modifying therapies from the CCNA imaging workgroup"}]},{"@type":"WebSite","@id":"https:\/\/ccna-ccnv.ca\/fr\/#website","url":"https:\/\/ccna-ccnv.ca\/fr\/","name":"Canadian Consortium on Neurodegeneration in Aging","description":"","publisher":{"@id":"https:\/\/ccna-ccnv.ca\/fr\/#organization"},"alternateName":"CCNA - CCNV","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ccna-ccnv.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-CA"},{"@type":"Organization","@id":"https:\/\/ccna-ccnv.ca\/fr\/#organization","name":"Canadian Consortium on Neurodegeneration in Aging","alternateName":"CCNA - CCNV","url":"https:\/\/ccna-ccnv.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-CA","@id":"https:\/\/ccna-ccnv.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/ccna-logo-on-white-background.jpg","contentUrl":"https:\/\/ccna-ccnv.ca\/wp-content\/uploads\/2025\/01\/ccna-logo-on-white-background.jpg","width":696,"height":696,"caption":"Canadian Consortium on Neurodegeneration in Aging"},"image":{"@id":"https:\/\/ccna-ccnv.ca\/fr\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/ccna_publication\/12232","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/ccna_publication"}],"about":[{"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/types\/ccna_publication"}],"author":[{"embeddable":true,"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/users\/19"}],"wp:attachment":[{"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/media?parent=12232"}],"wp:term":[{"taxonomy":"studies-relation","embeddable":true,"href":"https:\/\/ccna-ccnv.ca\/fr\/wp-json\/wp\/v2\/studies-relation?post=12232"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}